Margo A Brinton

US Patent:

8303946, Nov 6, 2012

Filed:

Sep 2, 2003

Appl. No.:

10/654273

Inventors:

Margo A. Brinton - Decatur GA, US
Wei Li - Wayland MA, US

Assignee:

Georgia State University Foundation, Inc. - Atlanta GA

International Classification:

C12N 15/00
C12N 15/33
C12N 15/86
C12Q 1/68
C12Q 1/70

US Classification:

424 931, 424 9321, 424 932, 435456, 435 5, 435 61

Abstract:

The present invention is directed to methods and compositions that are effective in the inhibition of viral replication. In particular, the methods and compositions are effective at interfering with the activity of host cell proteins required in viral replication. For example, an embodiment of the invention is directed to inhibition of flavivirus replication wherein the replication is effected by changing the normal interactions of the host cell protein TIAR or TIA-1.

US Patent:

20050244815, Nov 3, 2005

Filed:

Dec 15, 2004

Appl. No.:

11/012762

Inventors:

Margo Brinton - Decatur GA, US
Andrey Perelygin - Alpharetta GA, US

Assignee:

Georgia State University Research Foundation - Atlanta GA

International Classification:

C12Q001/70
C12Q001/68

US Classification:

435005000, 435006000

Abstract:

The present invention is directed to methods and compositions for identifying viral resistance genes and for identifying individuals having resistant or susceptible genotypes. Once identified as either resistant or susceptible, appropriate actions, such as vaccination, can be undertaken by the individuals. In particular, methods and compositions for identifying genes associated with resistance or susceptibility for flaviviruses are disclosed.

US Patent:

20070269828, Nov 22, 2007

Filed:

Apr 25, 2007

Appl. No.:

11/789687

Inventors:

Margo Brinton - Decatur GA, US
Andrey Perelygin - Alpharetta GA, US

International Classification:

C12Q 1/68

US Classification:

435006000

Abstract:

The present invention further provides a method of evaluating yellow fever virus susceptibility in a subject, which comprises obtaining a nucleic acid containing at least a portion of OAS gene from the subject, and determining whether the nucleic acid comprises SNPs relating to the susceptibility of the subject to yellow fever virus-associated condition. Also provided is a method of evaluating tick-borne encephalitis virus susceptibility in a subject, which comprises obtaining a nucleic acid containing at least a portion of OAS gene from the subject, and whether the nucleic acid comprises SNPs relating to the susceptibility of the subject to tick-borne encephalitis virus-associated condition.

US Patent:

20090186842, Jul 23, 2009

Filed:

Jul 16, 2007

Appl. No.:

11/879493

Inventors:

Margo A. Brinton - Decatur GA, US
Mohamed M. Emara - Atlanta GA, US

International Classification:

A61K 31/7105
C12N 7/01
C12N 5/06
A61P 31/12

US Classification:

514 44, 4352351, 435325

Abstract:

The present invention is directed to methods and compositions that are effective in the inhibition of viral replication. In particular, the methods and compositions are effective at interfering with the activity of host cell proteins required in viral replication. For example, an embodiment of the invention is directed to methods and compositions comprising RNA sequences to which the host cell proteins TIAR and/or TIA-1 bind.

US Patent:

20100166704, Jul 1, 2010

Filed:

Apr 7, 2008

Appl. No.:

12/082095

Inventors:

Margo A. Brinton - Decatur GA, US
Mohamed M. Emara - Roswell GA, US
Wei Li - Wayland MA, US

International Classification:

A61K 38/21
A61K 39/395
A61K 35/76
A61K 38/00
A61K 38/16
A61K 31/7088

US Classification:

424 854, 4241301, 424 936, 514 2, 514 12, 514 44 R

Abstract:

The present invention is directed to methods and compositions that are effective in the inhibition of viral replication. In particular, the methods and compositions are effective at interfering with the activity of host cell proteins required in viral replication. For example, an embodiment of the invention is directed to inhibition of flavivirus replication wherein the replication is affected by changing the normal interactions of the host cell protein TIAR or TIA-1.

US Patent:

54301351, Jul 4, 1995

Filed:

Jul 6, 1993

Appl. No.:

8/087016

Inventors:

Omana V. Nainan - Decatur GA
Harold S. Margolis - Lilburn GA
Betty H. Robertson - Chamblee GA
Margo A. Brinton - Atlanta GA
James W. Ebert - Lilburn GA

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

C07H 1700
C12P 2102
C12P 1934
C12N 1500

US Classification:

536 2372

Abstract:

The present invention relates, in general, to substantially pure preparations of the cynomolgus monkey hepatitis A viral isolates CY-145 and CY-55/JM-55; cDNAs of the genomic RNAs of cynomolgus monkey hepatitis A viral isolates CY-145 and CY-55/JM-55; a method of preventing hepatitis A in an animal; and vaccines comprising the cynomolgus monkey hepatitis A viral isolates CY-145 and CY-55/JM-55.